Mastopexy Market By Procedure Type (Standalone Mastopexy, Augmentation Mastopexy, Reduction Mastopexy, Reconstructive Mastopexy); By Technique (Crescent Lift, Periareolar Lift, Vertical Lift, Anchor or Inverted T Lift); By Application (Cosmetic Breast Contouring, Post-Pregnancy Breast Correction, Post-Weight-Loss Body Contouring, Breast Cancer Reconstruction and Symmetry Correction); By End User (Hospitals, Specialty Plastic Surgery Clinics, Ambulatory Surgical Centers, Cosmetic Surgery Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Mastopexy Market — Procedure Demand, Commercial Economics, and Strategic Outlook - (Updated On: 14-Aug-2026)

The Global Mastopexy Market is valued at USD 1.45 billion in 2025 and is projected to reach USD 2.21 billion by 2032, growing at a CAGR of 7.3%.

 

Mastopexy, commonly called breast-lift surgery, is a surgeon-delivered procedure that raises and reshapes sagging breasts by removing excess skin and repositioning supporting tissue. It can be performed as a stand-alone cosmetic procedure or combined with breast augmentation, reduction, or reconstructive surgery when patients require changes in both breast position and volume.

 

Demand is increasing through several distinct pathways: post-pregnancy breast changes, aging-related ptosis, major weight loss, combined augmentation-mastopexy, breast reduction with lifting, and selected post-cancer symmetry procedures. Commercially, the market is driven by procedure volume, surgeon fees, surgical-facility utilization, anesthesia, implants, and adjunctive products rather than a single standardized physical product.

 

The most useful demand indicator is therefore the number of mastopexy procedures performed each year. ASPS reported 153,616 U.S. breast-lift procedures in 2024, while ISAPS estimated 772,138 breast lifts globally in the same year. Combined procedures add further economic value because the surgical episode may include implants, tissue-support products, anesthesia, and additional facility services.

 

How Large Is Mastopexy Procedure Demand in the U.S. and Globally?

U.S. breast-lift demand remained stable in the latest complete ASPS dataset. The American Society of Plastic Surgeons reported 153,616 procedures in 2024 compared with 153,600 in 2023. ISAPS independently estimated 141,355 U.S. breast lifts in 2024 using a different survey and extrapolation methodology.

Globally, ISAPS estimated 772,138 breast-lift procedures in 2024, equal to 4.4% of approximately 17.42 million aesthetic surgical procedures performed by plastic surgeons worldwide. The 2023 ISAPS estimate was 963,580 procedures. The 2024 survey expanded from 1,600 participating surgeons to 2,975 and increased the number of individually reported locations from 23 to 32, changing the extrapolation base used for worldwide totals.

For market analysis, the U.S. figures from ASPS and ISAPS are best viewed as separate utilization benchmarks rather than combined estimates. The 2024 global volume shows that mastopexy remains a high-volume breast-aesthetic procedure supported by a large network of plastic surgeons, surgical facilities, and adjacent breast-device suppliers.

 

Why Is Demand for Mastopexy Increasing?

Pregnancy and postpartum breast changes create one of the largest recurring demand pools. CDC recorded 3,628,934 U.S. births in 2024, while UN DESA reports roughly 132 million births annually worldwide. Pregnancy, breastfeeding, and subsequent changes in breast volume can contribute to persistent ptosis, loss of upper-pole fullness, and altered breast contour, leading some patients to consider mastopexy after recovery and completion of childbearing.

Major weight loss is another growing source of breast-contouring demand. ASPS has linked lift and body-contouring procedures with excess or sagging skin following substantial weight reduction, including patients using GLP-1-based weight-management therapies. Once weight stabilizes, patients with breast deflation or significant skin laxity may consider mastopexy alone or as part of a broader body-contouring plan.

Aging also sustains demand because skin elasticity, breast-supporting tissue, and breast position change over time. Unlike a pharmaceutical market driven by disease incidence, mastopexy demand depends heavily on patient willingness to convert an anatomical or aesthetic concern into an elective surgical procedure. Surgeon availability, financing, recovery time, perceived outcome quality, and total procedure cost therefore directly influence market conversion.

Demand becomes more valuable per patient when breast lifting is combined with volume restoration or reduction. Providers can address ptosis, asymmetry, excess skin, and volume preferences within one surgical episode, expanding revenue beyond stand-alone mastopexy.

 

Which Mastopexy Techniques Shape Procedure Selection?

Mastopexy technique is selected according to the degree of breast ptosis, tissue laxity, breast volume, and the amount of reshaping required. The main incision approaches include crescent, periareolar, vertical, and anchor mastopexy, creating different levels of surgical complexity and resource requirements.

A crescent lift uses a limited incision along the upper areolar margin and is generally suited to very mild lifting or nipple-position adjustment. A periareolar or donut lift uses an incision around the areola and is commonly considered for mild ptosis, including selected procedures performed with augmentation.

The vertical or lollipop technique extends the incision around the areola and vertically toward the breast crease, providing greater ability to remove skin and reshape the breast in moderate ptosis. The anchor or inverted-T technique adds a horizontal incision within the inframammary fold and is commonly used when extensive skin removal and reshaping are required, including severe ptosis and some post-weight-loss cases.

From a market perspective, technique matters because more extensive correction can require longer operating time, greater facility resources, and more postoperative management, while combined augmentation can add implant-related expenditure.

 

Why Are Combined Breast Procedures Important to Mastopexy Market Revenue?

Combined augmentation-mastopexy represents one of the most commercially important overlaps in the market. ASPS reported 306,196 U.S. breast augmentations in 2024, and 79,921, or 26%, incorporated a breast lift. This indicates that a substantial group of breast-aesthetic patients seek both lifting and volume enhancement during the same treatment pathway.

A combined procedure expands the economic value of the surgical episode through surgeon services, anesthesia, operating-room use, implants, surgical consumables, postoperative garments, and follow-up care. It also connects mastopexy demand directly with breast-implant manufacturers and other surgical-product suppliers.

ASPS reports an average surgeon fee of USD 6,816 for breast-lift surgery, excluding anesthesia, operating-room facilities, and other related expenses. Applying that average fee to 153,616 ASPS-reported procedures produces more than USD 1 billion in implied annual U.S. surgeon-fee activity before facility, anesthesia, implant, and other procedure costs.

Cosmetic mastopexy is largely self-pay, making demand sensitive to household discretionary spending, patient financing, surgeon reputation, local pricing, and total bundled cost. Repeat or revision procedures can also generate additional activity when pregnancy, substantial weight change, aging, tissue relaxation, or previous surgical outcomes alter breast position over time.

 

How Does Breast-Cancer Reconstruction Create Mastopexy Demand?

Breast-cancer reconstruction creates a smaller but clinically and commercially important mastopexy pathway. SEER projects 321,910 new female breast-cancer diagnoses in the United States in 2026, while WHO estimates approximately 2.4 million women were diagnosed globally in 2024. Selected patients undergoing mastectomy, reconstruction, or oncoplastic breast-conserving surgery may require surgery on the opposite breast to improve symmetry.

In the United States, the Women's Health and Cancer Rights Act requires applicable health plans that provide mastectomy-related benefits to cover reconstruction and surgery of the opposite breast when needed to produce a symmetrical appearance. This gives selected reconstructive mastopexy procedures a reimbursement pathway that differs materially from elective cosmetic breast lifting.

Clinical utilization confirms the role of symmetry surgery. A U.S. NSQIP analysis of 5,429 unilateral free-flap breast reconstructions performed during 2016–2020 found that about 8% of patients underwent simultaneous contralateral mastopexy or reduction. Hospitals, reconstructive surgeons, and breast-device suppliers therefore participate in a medically supported mastopexy segment alongside the larger private-pay aesthetic market.

 

Which Companies Participate in the Mastopexy Market?

The provider side of the mastopexy market is fragmented across plastic surgeons, aesthetic clinics, ambulatory surgical facilities, and hospitals. Medical-device companies participate primarily through implants, scaffolds, and adjunct products used in selected combined or reconstructive procedures.

BD participates through GalaFLEX Scaffold, an absorbable soft-tissue reinforcement product used as an adjunct to sutures in selected breast procedures. Its commercial relevance is greatest when additional internal support is incorporated into breast lifting, augmentation, or revision surgery.

Johnson & Johnson MedTech participates through the MENTOR breast-implant portfolio. In 2025, the company reported that MENTOR implants were available in 118 countries and had been selected by more than 9 million women cumulatively worldwide, giving the business broad exposure to augmentation and reconstructive breast surgery.

AbbVie/Allergan Aesthetics participates through Natrelle breast implants. In 2025, AbbVie announced a Vizient supplier agreement for Natrelle, expanding access through a network representing more than half of U.S. healthcare organizations.

Establishment Labs competes through Motiva implants and its Preservé platform, which is positioned for primary augmentation and mastopexy-augmentation procedures. By 2026, Establishment Labs reported five million Motiva devices delivered cumulatively since 2010 and commercial activity across more than 100 countries.

 

Which Countries Lead Global Mastopexy Demand?

The United States and Brazil are two of the largest national mastopexy procedure markets. ISAPS estimated 141,355 breast lifts in the United States and 137,736 in Brazil in 2024. Together, the two countries represented approximately 36% of the 772,138 breast lifts estimated worldwide.

The United States combines extensive plastic-surgeon capacity, high awareness of cosmetic procedures, patient-financing options, and a legally protected post-mastectomy symmetry pathway. These factors support both self-pay cosmetic mastopexy and reconstructive procedures.

Brazil has a large aesthetic-surgery ecosystem, substantial breast-surgery activity, and strong consumer acceptance of cosmetic surgery. Other markets also benefit from private-pay healthcare and medical tourism. Türkiye, Mexico, the UAE, Thailand, and Tunisia have notable international-patient participation across aesthetic procedures, supporting opportunities for cross-border breast surgery.

Regional mastopexy demand is therefore influenced by surgeon density, disposable income, financing availability, procedure pricing, device availability, regulatory access, and international patient flows.

 

What Is the Mastopexy Market Outlook Through 2032?

The Mastopexy Market is projected to grow from USD 1.45 billion in 2025 to USD 2.21 billion by 2032 at a CAGR of 7.3%. Growth is supported by sustained breast-lift procedure volumes, post-pregnancy contouring demand, major-weight-loss patients, combined augmentation-mastopexy, reconstructive symmetry surgery, and rising value per surgical episode.

The United States has an established base of more than 150,000 annual breast-lift procedures according to ASPS, while ISAPS estimated more than 772,000 procedures globally in 2024. Combined augmentation-mastopexy broadens revenue opportunities for surgeons, facilities, and implant suppliers, while reconstructive symmetry provides a separate reimbursed pathway for selected breast-cancer patients.

Through 2032, the most important commercial indicators will be annual procedure volume, average procedure economics, augmentation-mastopexy penetration, consumer financing, surgeon capacity, reconstructive utilization, implant and scaffold adoption, regional pricing, and expansion of aesthetic-surgery infrastructure.

 

Mastopexy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.45 Billion
Revenue Forecast in 2032	USD 2.21 Billion
Overall Growth Rate	CAGR of 7.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Procedure Type, By Technique, By Application, By End User, By Geography
By Procedure Type	Standalone Mastopexy, Augmentation Mastopexy, Reduction Mastopexy, Reconstructive Mastopexy
By Technique	Crescent Lift, Periareolar Lift, Vertical Lift, Anchor or Inverted T Lift
By Application	Cosmetic Breast Contouring, Post-Pregnancy Breast Correction, Post-Weight-Loss Body Contouring, Breast Cancer Reconstruction and Symmetry Correction
By End User	Hospitals, Specialty Plastic Surgery Clinics, Ambulatory Surgical Centers, Cosmetic Surgery Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Brazil, UK, Germany, France, China, India, Japan, South Korea, UAE, Mexico, etc.
Market Drivers	- Increasing demand for aesthetic breast procedures after pregnancy, aging, and major weight loss. - Rising adoption of combined augmentation mastopexy procedures. - Growing availability of advanced plastic surgery infrastructure and patient financing options.
Customization Option	Available upon request